thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-21. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
It is perfectly legitimate to write [H+] for the hydronium ion concentration, since the state of solvation of the proton is constant (in dilute solutions) and so does not affect the equilibrium concentrations. Kw varies with variation in ionic strength and/or temperature. The concentrations of H+ and OH− are not independent quantities. Most commonly [OH−] is replaced by Kw[H+]−1 in equilibrium constant expressions which would otherwise include hydroxide ion. Solids also do not appear in the equilibrium constant expression, if they are considered to be pure and thus their activities taken to be one. An example is the Boudouard reaction:
18 March to 28 February 1971 The 198th Light Infantry Brigade and ARVN 6th Regiment, 2nd Division launch Operation Geneva Park to pacify Quảng Ngãi Province. the operation results in 2,337 PAVN killed and 67 captured, U.S. losses are 231 killed.
NESHAP: Listed as a Hazardous Air Pollutant (HAP) Comprehensive Environmental Response, Compensation, and Liability Act: Reportable Quantity (RQ) = 100 lb Emergency Planning and Community Right-To-Know Act, EPA's Toxics Release Inventory: A listed substance subject to RCRA reporting requirements RCRA Listed Hazardous Waste: substance - U238
=== Independent investigations === In June 2021, the NIH announced that a set of sequence data had been removed from the Sequence Read Archive (SRA) in June 2020. The removal was performed according to standard practice at the request of the investigators who owned the rights to the sequences, with the investigators' rationale that the sequences would be submitted to another database. The investigators subsequently published a paper in an academic journal the same month they were removed from the NIH database which described the sequences in detail and discussed their evolutionary relationship to other sequences, but did not include the raw data. Virologist David Robertson said that it was difficult to conclude it was a cover-up rather than the more likely explanation: a mundane deletion of data without malfeasance. The missing genetic sequence data was restored in a correction published 29 July 2021 after it was stated to be a copy-edit error. In September 2024, a study published in Cell found genetic evidence that COVID-19 may have originated from the illegal trade of infected raccoon dogs in Wuhan, China, supporting the zoonotic transmission scenario. Swabs taken from the Huanan Seafood Wholesale Market in January 2020, which tested positive for coronavirus, contained large amounts of genetic material from raccoon dogs.
Sources: en.wikipedia.org
From 1948 to 1994, international rugby relations with apartheid South Africa, and also the non-integrated nature of rugby within the country drew frequent controversy. South Africa remained a member of the International Rugby Board (IRB) throughout the apartheid era. Halt All Racist Tours was established in New Zealand in 1969 to oppose continued tours to and from South Africa. Though contacts were restricted after the Gleneagles Agreement in 1977, there were controversial tours in 1980 by the British Lions and by France, in 1981 by Ireland, and in 1984 by England. South Africa toured New Zealand in 1981. South Africa were excluded from the first two Rugby World Cups, in 1987 and 1991. Racially selected New Zealand sports teams toured South Africa until the 1970 All Blacks rugby tour allowed Māori to go under the status of 'honorary whites'. The issue affected not only black South Africans, but also indigenous New Zealanders and to a lesser extent indigenous Australians. Many major rugby union international sides had few non-white players, but theoretically, a side such as Fiji would have been frowned upon. Apartheid South Africa's last foreign tour was to New Zealand in 1981, prior to the system's dismantlement in 1991 and new elections in 1994.
sex linkage The presence of a particular gene or DNA sequence on a sex chromosome (in mammals either the X chromosome or the Y chromosome) rather than on an autosome; these genes are said to be sex-linked. Expression of sex-linked genes varies by organism depending on the mechanism of sex determination and the types of sex chromosomes present, but the associated phenotypes often exclusively appear in either the homogametic or heterogametic sex.
Despite his triumph in Rome, he lost his opening round match at the French Open. During the grass court season, Zverev made another singles final and again faced Federer at the Halle Open, but could not defeat him this time. He and his brother also finished runner-up in the doubles event to Łukasz Kubot and Marcelo Melo. At Wimbledon, he achieved his best result at a major event to date, ultimately losing in the fourth round to the previous year's runner-up Milos Raonic in a tight five-set match. Back on hard courts, Zverev won his last two titles of the season in August. He won the Washington Open as well as a second consecutive Masters title at the Canadian Open, only dropping a single set at each tournament in each of his opening matches. Notably, he needed to save three match points in his first match in Canada against Richard Gasquet, including a 49 shot rally. He then defeated Roger Federer in the final to become the first player outside of the Big Four to win multiple Masters titles in the same season since David Nalbandian in 2007. Despite this success, he was upset in the second round of the US Open by fellow Next Gen player Borna Ćorić. At the end of the season, Zverev qualified for both the inaugural Next Generation Finals as one of the top seven 21-and-under players, and the ATP Finals as one of the top eight players in the world. He opted to skip the former event to focus on the latter. At the ATP Finals, Zverev was grouped with Roger Federer, Marin Čilić, and Jack Sock.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.